Digital Medicine Innovation Cycle Checklist

| Solution Name: | Not Done | Proposed | Completed | Date: |
|----------------|----------|----------|-----------|-------|
|----------------|----------|----------|-----------|-------|

| IML | Overall Description | Clinical | Business | Regulatory | Technology |
|-------------------------------------|--|--|---|---|---|
| 1. Need | Insights into unmet medical needs and available solutions | Unmet need statement Disease state characterization | Needs screening & selection Existing solutions characterization | Regulatory Familiarization | State-of-the-Art Summary |
| 2. Idea | Potential solution to unmet need described, evaluated, and selected | Workflow Scenario Updated need statement Envisioned benefit statement Feedback from 5+ clinical stakeholders | Competitive landscape Envisioned Value Proposition Key stakeholders identified Reimbursement familiarization | Medical device determination Comparables identified | Idea screening and selection System and module requirement specification Interface mock-upsl Institutional IP disclosure |
| 3. Proof of Concept (PoC) | Key component concepts validated in models and value proposition tested | Feedback from clinical stakeholders in 5+ settings Updated need statement and workflow scenario Target outcomes | Competing solutions characterization Preliminary value proposition Path-to-Payment plan Stakeholder map Business protection model | Preliminary regulatory classification and pathway Preliminary indications for use Preliminary risk and hazard analysis | Preliminary system & software architecture Key module PoC prototypes Demonstration results Updated institutional IP disclosure Key in-sourcing requirements |
| 4. Proof of Feasibility (PoF) | Feasibility of whole solution demonstrated in models and in feedback from stakeholders | Feedback from clinical stakeholders in 20+ settings Updated need statement and Use Case scenario/ workflow Updated target outcomes | Feedback from 5+ economic buyers Preliminary business model Development plan Key relationships identified Business advisory board | Draft essential requirements checklist Draft product claims Draft instructions for use Institutional approval request(s) Cyber security plan Submission pathway defined | Product Requirement Document (PRD Software & hardware architecture "Works Like" prototypes Essential experiment results Risk mitigation & interoperability plan Provisional IP filing & initial FTO review Key in-sourcing plans |

| 5. Proof of Value (POV) | The potential of the solution to work and create value for stakeholders is demonstrated | Feedback from 100+ users Feedback from 5+ KOLs Medical advisory board Clinical pilot Clinical trial endpoints | Incorporation & Founder's agreement Key management team committed Investor ready business plan Feedback from 10+ economic buyers Initial seed investment Key relationships formalized | Essential requirements checklist Application to regulatory authority submitted Clinical Investigation approval(s) Protected Health Information (ePHI) plans | "Works Like, Looks Like" prototypes Essential technical experiments results Interoperability validation IP search report Key in-sourcing requirements committed cGMP compliant pilot medical software & production enviroment(s) |
|---|---|---|---|--|--|
| 6. Initial Clinical Trials | Regulated production of prototypes and collection of clinical and economic data | Endpoints achieved in Feasibility clinical trials Demo feedback from 20+ users Peer reviewed publication(s) submitted | Value quantification Feedback from 20+ economic buyers 1st Institutional Investment | GDPR/HIPAA compliance Security and vulnerability certifications Data requirements confirmation Pre-submission sent | Updated specification & experimental validation All in-sourcing requirements achieved Full IP application |
| 7. Validtion of Solution (VoS) | The solution is shown to be effective and its value to all stakeholders is validated | Endpoints achieved in pivotal clinical trials Peer reviewed publication(s) accepted | Purchasing intent from 10+ buyers Second round of institutional investment | Submission of technical file to regulatory body | Quality assured process validation (cGMP) Updated specification & experimental validation |
| 8. Approval & Launch (A&L) | Institutional and regulatory approval received and sales launch | Training materials & Support established Specialty medical groups review in place | Initial sales Regionalization plans | Registration and listing CMS/Public Coverage and CPT/DRG code determination | Finalized cGMP production environment Regionalization requirements |
| 9. Clinical Use (Use) | The solution is used successfully in day-to-day clinical practice | Included in local practice guidelines Peer reviewed publications | Profitable sales New markets launched | Monitoring/ inspections | Regionalization implemented Improvement plan |
| 10. Standard of Care (SoC) | The solution is recognized as the standard of care | Recommended practice by medical specialty | Dominant market share Health economics study | Product Obsolescence Plan | Component Obsolescence Plan |